This retrospective cross-sectional study assessed results of routine infectious disease screening among unaccompanied minors on arrival in Germany. Migration-related exposures can increase risk for communicable diseases, and early detection permits timely treatment and public health responses. The relationship between characteristics of the migration journey and infectious disease prevalence in this population is not well characterized; the study therefore examined both prevalence and associations with journey attributes.
Researchers used standardized, case-specific health assessments performed by the Public Health Service in one Bavarian district. Routine data were collected over thirteen consecutive years (2010–2022). The dataset included a full cohort of 237 unaccompanied minors who underwent legally mandated screening. From within that cohort, a subgroup of 129 minors had documented migration journey information and were analyzed to describe socio-epidemiological profiles and to explore patterns according to the number of transit countries, journey duration, and modes of migration.
Screening targeted multiple conditions commonly considered in migrant health assessments: tuberculosis, hepatitis A, hepatitis B, hepatitis C, scabies, and intestinal parasitic infections. The authors first described prevalence of detected infections in the full cohort, then characterized the subgroup with migration-history data to explore possible associations between journey characteristics and infectious disease detection.
In the full cohort of 237 unaccompanied minors, at least one infectious disease was detected in 61.2% of individuals. The screening therefore identified a substantial burden of communicable disease on arrival in this legally mandated assessment program. Specific prevalence estimates for each infection across the full cohort were reported in the primary article (screened conditions listed above), and overall positivity was used as an indicator of the proportion with one or more detected infections.
The subgroup with documented migration journey information included 129 minors. In this subgroup, 65.1% had at least one detected infectious disease, a prevalence broadly similar to the full cohort. Sociodemographic features of the subgroup were: 79.8% male and 55.0% aged between 13.5 and 16.5 years.
Regional patterns were noted for specific infections: tuberculosis prevalence was highest among participants from Sub-Saharan Africa (20.0%, 95% CI 11.2–32.7). Hepatitis B predominated among minors from North Africa and Southeast Europe. Regarding migration journeys, 52.9% of the subgroup passed through three to four countries, and 72.1% reported using two different modes of travel. The authors observed that infectious disease positivity was numerically higher among minors with longer documented migration journeys, but emphasized that confidence intervals were wide.
The study indicates that infectious disease positivity was common among unaccompanied minor refugees in this Bavarian district cohort, with similar overall prevalence patterns in both the full cohort and the migration-history subgroup. Regional origin appeared to correspond with different patterns of specific infections (for example, higher tuberculosis prevalence among Sub-Saharan African participants and higher hepatitis B prevalence among North African and Southeast European minors).
Migration journey characteristics—such as number of transit countries, journey duration, and modes of travel—provided descriptive context for interpreting screening results. However, the observed numerical increase in positivity with longer journeys lacked robust statistical support in this dataset. The authors therefore recommend that migration history be recorded carefully during clinical assessment, as it can supply useful context for screening and case management even when formal associations are not definitive.
Practical implications include support for structured health screening after arrival of unaccompanied minors and integration of migration-history documentation into routine public health assessments to inform follow-up, treatment, and prevention strategies.
The authors explicitly note several limitations that affect interpretation of associations between journey characteristics and infectious disease prevalence. The subgroup analyses were constrained by a limited sample size (129 with migration-history data), resulting in wide confidence intervals and reduced statistical power. Potential confounding factors were present and not fully controlled for in the descriptive analyses. Because the study used routinely collected data from a single Bavarian district over 2010–2022, findings may not generalize to other settings or time periods. Details such as exact per-infection prevalence values across all strata and any additional statistical estimates not described in the abstract were reported in the primary article; if not presented there, they were not available in this source summary.
In this retrospective analysis of mandated screening data from 2010 to 2022, a high proportion of unaccompanied minors had at least one detected infectious disease on arrival. While migration journey characteristics offered descriptive insight into patterns of infections, differences by journey duration and other travel traits were not supported by clear statistical evidence in this dataset. The authors conclude that these findings support continued structured screening of unaccompanied minors after arrival and careful documentation of migration history during clinical assessment to aid detection, treatment, and prevention efforts. Further research with larger samples and more detailed adjustment for confounding would be required to establish stronger evidence for associations between specific journey characteristics and infectious disease risk.